Prof. Yingwei Xue 薛英威
Chief Physician, Professor
Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of gastric cancer and abdominal tumors. Focuses on standardized radical surgery and comprehensive care for digestive tract cancers, including modified total gastrectomy and proximal gastrectomy techniques.
Dr. Xue holds a medical doctorate from Harbin Medical University and serves as Professor and Chief of Gastrointestinal Surgery at Harbin Medical University Cancer Hospital. With over 20 years of experience in gastric tumor diagnosis and treatment, Dr. Xue conducts basic research on gastric cancer pathogenesis. The doctor has published over 60 papers, including 9 SCI-indexed articles, and received five science and technology progress awards.
Professional roles
- Vice Chair, Gastric Cancer Professional Committee, China Anti-Cancer Association
- Chair, Gastric Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Vice Chair, General Surgery Professional Committee, Heilongjiang Medical Association
- Member, Geriatric Oncology Professional Committee, Chinese Medical Association
Name order: in Chinese the family name comes first (Xue Yingwei). Papers usually list the name as Yingwei Xue or Xue Y.
Selected publications
126 papers on PubMed matched by name and affiliation; 83 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Differ, 2026 (senior author): MCAT-mediated mitochondrial fatty acid metabolism regulates Lauren subtype divergence and suppresses gastric cancer progression through ROS/P53-dependent mitophagy and ferroptosis. PubMed 42711380
- Sci Rep, 2025 (senior author): LRP12 promotes gastric cancer progression through AKT/mTOR signaling and M2 macrophage-mediated immunosuppression. PubMed 41276539
- J Inflamm Res, 2025 (senior author): Prognostic Value of Inflammatory Indices in Papillary Gastric Carcinoma with Different Proportions of Papillary Components. PubMed 40687144
- World J Gastroenterol, 2025 (senior author): Machine learning-based reconstruction of prognostic staging for gastric cancer patients with different differentiation grades: A multicenter retrospective study. PubMed 40248057
- J Inflamm Res, 2024 (senior author): Integrating Machine Learning and the SHapley Additive exPlanations (SHAP) Framework to Predict Lymph Node Metastasis in Gastric Cancer Patients Based on Inflammation Indices and Peripheral Lymphocyte Subpopulations. PubMed 39606641
- World J Gastroenterol, 2024 (senior author): Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors. PubMed 39494097
- Transl Cancer Res, 2024 (senior author): Machine learning methods predict recurrence of pN3b gastric cancer after radical resection. PubMed 38617507
- Heliyon, 2024 (senior author): Clinical significance of systemic inflammation response index and platelet-lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. PubMed 38420481
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion